Xilio Therapeutics, Inc.,
a clinical-stage biotechnology company, engages in the discovery and
development of tumor-activated immuno-oncology therapies.
- Sector: Healthcare
- Industry: Biotechnology
- Full Time Employees: 73
- Founded in 2016
- Headquartered in Waltham, Massachusetts
- https://xiliotx.com
Ticker: XLO
October
22, 2021 : initial public offering of 7,353,000 shares of its common
stock at a price to the public of $16.00 per share.
No comments:
Post a Comment